Nerve-Sparing Therapy with Oncolytic Herpes Virus for Cancers with Neural Invasion
- 1 November 2007
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 13 (21), 6479-6485
- https://doi.org/10.1158/1078-0432.ccr-07-1639
Abstract
Purpose: The invasion of cancer cells along nerves is an ominous pathologic finding associated with poor outcomes for a variety of tumors, including pancreatic and head and neck carcinomas. Peripheral nerves may serve as a conduit for these cancers to track into the central nervous system. Cancer progression within nerves and surgical resection of infiltrated nerves result in a permanent loss of neural function, potentially causing cosmetic and functional morbidity. Herpes simplex viruses (HSV) have utility for gene transfer into nerves and as oncolytic agents. We studied the use of an attenuated HSV, NV1023, as treatment for cancers with neural invasion. Experimental Design and Results: NV1023 injection into the sciatic nerves of nude mice had no toxic effect on nerve function, whereas similar doses of wild-type HSV-1 (F′ strain) caused complete nerve paralysis within 4 days and 100% mortality at day 6. NV1023 showed effective cytotoxicity in vitro on three neurotrophic human carcinoma cell lines, including pancreatic (MiaPaCa2), squamous cell (QLL2), and adenoid cystic (ACC3) carcinomas. A model of neural invasion was established by implanting human carcinoma cells in the sciatic nerves of nude mice. All control group mice developed left hind limb paralysis 5 to 7 weeks after tumor injection, whereas animals treated with NV1023 maintained intact nerve function and showed significant tumor regression (P < 0.0001). Conclusions: These results show that NV1023 oncolytic therapy may effectively treat cancers with neural invasion and preserve neural function. These findings hold significant clinical implications for patients with cancer neural invasion.Keywords
This publication has 24 references indexed in Scilit:
- Phase I, Open-Label, Dose-Escalating Study of a Genetically Engineered Herpes Simplex Virus, NV1020, in Subjects with Metastatic Colorectal Carcinoma to the LiverHuman Gene Therapy, 2006
- Real‐time diagnostic imaging of tumors and metastases by use of a replication‐competent herpes vector to facilitate minimally invasive oncological surgeryThe FASEB Journal, 2006
- Combination of mutated herpes simplex virus type 1 (G207 virus) with radiation for the treatment of squamous cell carcinoma of the head and neckEuropean Journal Of Cancer, 2005
- Treatment of aggressive thyroid cancer with an oncolytic herpes virusInternational Journal of Cancer, 2004
- Up‐regulation of GADD34 mediates the synergistic anticancer activity of mitomycin C and a γ134.5 deleted oncolytic herpes virus (G207)The FASEB Journal, 2004
- Oncolytic Herpesvirus Effectively Treats Murine Squamous Cell Carcinoma and Spreads by Natural Lymphatics to Treat Sites of Lymphatic MetastasesHuman Gene Therapy, 2002
- Therapeutic Efficacy of G207 in a Novel Peripheral Nerve Sheath Tumor ModelExperimental Neurology, 2001
- Cytokine Gene Transfer Enhances Herpes Oncolytic Therapy in Murine Squamous Cell CarcinomaHuman Gene Therapy, 2001
- In Vivo Behavior of Genetically Engineered Herpes Simplex Viruses R7017 and R7020. II. Studies in Immunocompetent and Immunosuppressed Owl Monkeys (Aotus trivirgatus)The Journal of Infectious Diseases, 1990
- Characterization of Herpes Simplex Virus Strains Differing in their Effects on Social Behaviour of Infected CellsJournal of General Virology, 1968